Theravance Biopharma (TBPH) Competitors $11.53 +0.06 (+0.52%) Closing price 04:00 PM EasternExtended Trading$11.53 0.00 (0.00%) As of 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TBPH vs. NAMS, APGE, RXRX, DNLI, VCEL, AGIO, CGON, KNSA, BEAM, and IDYAShould you be buying Theravance Biopharma stock or one of its competitors? The main competitors of Theravance Biopharma include NewAmsterdam Pharma (NAMS), Apogee Therapeutics (APGE), Recursion Pharmaceuticals (RXRX), Denali Therapeutics (DNLI), Vericel (VCEL), Agios Pharmaceuticals (AGIO), CG Oncology (CGON), Kiniksa Pharmaceuticals International (KNSA), Beam Therapeutics (BEAM), and IDEAYA Biosciences (IDYA). These companies are all part of the "pharmaceutical products" industry. Theravance Biopharma vs. Its Competitors NewAmsterdam Pharma Apogee Therapeutics Recursion Pharmaceuticals Denali Therapeutics Vericel Agios Pharmaceuticals CG Oncology Kiniksa Pharmaceuticals International Beam Therapeutics IDEAYA Biosciences Theravance Biopharma (NASDAQ:TBPH) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations. Do analysts recommend TBPH or NAMS? Theravance Biopharma presently has a consensus target price of $16.60, suggesting a potential upside of 43.97%. NewAmsterdam Pharma has a consensus target price of $42.89, suggesting a potential upside of 104.04%. Given NewAmsterdam Pharma's stronger consensus rating and higher probable upside, analysts clearly believe NewAmsterdam Pharma is more favorable than Theravance Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Theravance Biopharma 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.67NewAmsterdam Pharma 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals hold more shares of TBPH or NAMS? 99.1% of Theravance Biopharma shares are held by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 6.9% of Theravance Biopharma shares are held by insiders. Comparatively, 20.8% of NewAmsterdam Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is TBPH or NAMS more profitable? Theravance Biopharma has a net margin of -89.38% compared to NewAmsterdam Pharma's net margin of -397.45%. Theravance Biopharma's return on equity of -32.37% beat NewAmsterdam Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Theravance Biopharma-89.38% -32.37% -16.48% NewAmsterdam Pharma -397.45%-37.34%-33.45% Does the media refer more to TBPH or NAMS? In the previous week, Theravance Biopharma and Theravance Biopharma both had 4 articles in the media. NewAmsterdam Pharma's average media sentiment score of 0.80 beat Theravance Biopharma's score of 0.65 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Theravance Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive NewAmsterdam Pharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, TBPH or NAMS? Theravance Biopharma has a beta of -0.02, indicating that its share price is 102% less volatile than the S&P 500. Comparatively, NewAmsterdam Pharma has a beta of -0.03, indicating that its share price is 103% less volatile than the S&P 500. Which has better earnings & valuation, TBPH or NAMS? Theravance Biopharma has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTheravance Biopharma$65.27M8.83-$56.42M-$1.18-9.77NewAmsterdam Pharma$45.56M51.80-$241.60M-$1.88-11.18 SummaryTheravance Biopharma beats NewAmsterdam Pharma on 10 of the 16 factors compared between the two stocks. Get Theravance Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TBPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TBPH vs. The Competition Export to ExcelMetricTheravance BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$573.51M$2.44B$5.62B$9.30BDividend YieldN/A1.79%4.25%4.03%P/E Ratio-9.779.1428.5719.58Price / Sales8.83676.50424.2194.37Price / CashN/A164.3436.0257.93Price / Book3.234.608.135.54Net Income-$56.42M$30.99M$3.24B$257.73M7 Day Performance2.76%0.77%2.03%0.95%1 Month Performance7.86%23.11%8.29%10.68%1 Year Performance16.82%-5.46%28.40%15.67% Theravance Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TBPHTheravance Biopharma1.787 of 5 stars$11.53+0.5%$16.60+44.0%+22.4%$573.51M$65.27M-9.77110Analyst DowngradeNAMSNewAmsterdam Pharma2.747 of 5 stars$19.46-2.0%$42.89+120.4%+11.6%$2.23B$45.56M-10.354APGEApogee Therapeutics3.0861 of 5 stars$39.24-17.3%$99.00+152.3%-19.0%$2.19BN/A-10.9091High Trading VolumeRXRXRecursion Pharmaceuticals1.81 of 5 stars$4.93-6.5%$7.00+42.0%-36.8%$2.14B$58.84M-2.79400High Trading VolumeDNLIDenali Therapeutics4.6691 of 5 stars$14.25-3.0%$33.71+136.6%-35.7%$2.13B$330.53M-5.34430VCELVericel3.7273 of 5 stars$39.41-5.6%$61.14+55.1%-17.9%$2.10B$237.22M1,314.10300News CoveragePositive NewsAGIOAgios Pharmaceuticals4.3898 of 5 stars$35.21-2.4%$58.60+66.4%-14.5%$2.09B$36.50M3.13390News CoverageAnalyst RevisionCGONCG Oncology2.5817 of 5 stars$26.25-2.4%$58.67+123.5%-26.9%$2.05B$1.14M-17.3861News CoverageGap DownKNSAKiniksa Pharmaceuticals International3.5328 of 5 stars$27.95+0.3%$38.80+38.8%+35.8%$2.03B$423.24M-111.80220News CoveragePositive NewsUpcoming EarningsBEAMBeam Therapeutics2.2658 of 5 stars$19.18-4.1%$48.75+154.2%-21.2%$2.01B$63.52M-4.16510IDYAIDEAYA Biosciences3.5606 of 5 stars$21.16-4.3%$53.42+152.4%-43.6%$1.94B$7M-5.8980 Related Companies and Tools Related Companies NAMS Alternatives APGE Alternatives RXRX Alternatives DNLI Alternatives VCEL Alternatives AGIO Alternatives CGON Alternatives KNSA Alternatives BEAM Alternatives IDYA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TBPH) was last updated on 7/15/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theravance Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theravance Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TBPH Stock Alerts